Kyverna Therapeutics Inc. (KYTX) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, KYTX scores 35 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

• Fundamental Cash Engine: 7 / 20. Per the RQD rating, ROIC is -35% and FCF yield is 0%. Per the SEC financials, FY 2025 operating income was $-169.8M and free cash flow was $-153.7M against zero reported revenue. For a prospective investor, this pillar signals that the company is consuming capital rather than generating it, so the equity case rests on future pipeline outcomes rather than current cash earnings.
• Whale / 13F Flow: 3 / 20. The RQD rating reflects institutional accumulation and options positioning as weak. The holders section is unavailable in source data, so the underlying flow detail cannot be verified here; the low score is the only available read.
• Insider Conviction: 5 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow is scored low. The insider transaction detail is not provided in the holders section, so the reasoning behind the score cannot be traced to specific trades.
• Macro Regime Fit: 10 / 20. Per the RQD rating, beta is 1.0 and sector sensitivity is a moderate drag. A prospective investor should expect the stock to move in line with the broader market, with no defensive cushion from the business model itself.
• Forensic Balance Sheet: 10 / 20. Per the RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 0.11. Per the SEC financials, cash rose to $124.1M against debt of $24.7M at FY 2025. Leverage is modest, but the Piotroski score is weak and the company's cash burn is large relative to its cash balance, so runway is a central question.

Investor implications. The upside case depends on clinical and commercial progress that the source data does not quantify. The valuation tradeoff is that a $361.8M market cap, per the market data, is being paid for a company with zero revenue and a deeply negative ROIC. Second-order risk comes from the cash burn: continued losses at the FY 2025 pace would require additional financing or further dilution, which the source data does not address. This analysis is educational and is not personalized financial advice.

Kyverna Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company is classified in this industry with a market capitalization of $0.4B. The source data does not describe the company's specific products, customers, or revenue model. Per the SEC financials, reported revenue is $0.0M for each period shown, indicating no product revenue in the reported years.

Per the SEC financials, the company reported operating losses in every period shown, widening from $-62.4M in FY 2023 to $-169.8M in FY 2025. Gross, operating, and net margins are 0% per the market data, consistent with zero reported revenue. Per the RQD rating, ROIC is -35%, Altman Z is 2.5, and Piotroski F is 3/9. Cash increased from $96.6M to $124.1M between FY 2024 and FY 2025 with debt of $24.7M at FY 2025, so the balance sheet carries modest leverage against a rapidly growing cash burn.

Per the recent news and catalysts section, six items are tagged to KYTX:

• Stock-movement coverage (ChartMill, Stocktwits): Both items discuss market action and institutional positioning, with the Stocktwits headline referencing an after-hours rally. The source does not provide the magnitude or cause of the move beyond the headline.
• Clinical/scientific coverage (Seeking Alpha, Stock Titan): The Seeking Alpha piece characterizes the science as fascinating but the commercial outlook as tricky. The Stock Titan item reports that a cell therapy showed sustained benefit after one dose for stiff person syndrome and that Kyverna will present data. This is the most concrete catalyst in the feed, though the source gives no trial size or data timing.
• Estimates and ownership coverage (TradingView, MarketBeat): Both reference analyst estimates and institutional ownership, but neither item's content is included in the source beyond the headline.

The light and impact labels are YELLOW for most items, with one GREEN "CATALYST" item (Stocktwits). Risk watch items are the commercial uncertainty flagged by Seeking Alpha and the continuing cash burn in the financials. Per the butterfly supply-chain graph, there are no proprietary signals and no supply-chain links recorded.

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The one sector-level read available is the beta of 1.0 per the market data, which indicates market-level sensitivity rather than a documented chain of dependencies. A prospective investor should treat any ripple analysis for this name as unsupported by the current data.

• What is the cash runway at the FY 2025 burn rate of $-153.7M free cash flow against $124.1M of cash, and what financing is needed to fund operations?
• What is the timing, size, and endpoint of the stiff person syndrome data referenced in the news feed, and how does it affect the commercial outlook flagged by Seeking Alpha?
• What revenue or partnership arrangements, if any, exist to generate future product income, given zero reported revenue across all periods?
• Who holds the shares and how have insiders and institutions traded recently, since the holders section is unavailable?
• Why is EPS reported as N/A for every period, and what is the share count and dilution history?